CUONG DO JOINS ADAGENE'S BOARD OF DIRECTORS, AUDIT COMMITTEE

KUALA LUMPUR, Nov 22 (Bernama) -- Adagene Inc (Adagene), a company transforming the discovery and development of antibody-based therapies, has appointed Cuong Do as an independent director.

In a statement, the company said Do will also serve as an audit committee member.

Adagene co-founder, chief executive officer (CEO) and board chairman, Dr Peter Luo said he is delighted to welcome Do to the board as the company approaches significant milestones and engage in business development activities with major strategic considerations.

Meanwhile, Do said he was excited to join the Adagene board and doing what he can to help advance the programmes to help the patients.

“Adagene has ground-breaking innovations that can improve the efficacy and safety of immunotherapies.

“I look forward to working with the company and our partners to advance the programmes and benefit patients,” he said.

Do is also the president and CEO of BioVie Inc, a clinical-stage company developing innovative therapies for Alzheimers, Parkinson's and refractory ascites.

Prior to BioVie, he was the president of Samsung’s Global Strategy Group where he helped to set the strategic direction for Samsung Group’s diverse business portfolio, including the growth of its biologics businesses.

-- BERNAMA